Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...